Musk backed german CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine

Musk backed german CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK https://www.curevac.com/wp-content/uploads/2023/05/20230508-Curevac-Announces-Dosing-of-First-Participant-in-Phase-1-2-Flu-Study.pdf

---

visibility 86

chat_bubble_outline 0

thumb_up0